George Petrocheilos is the Co-Founder and Managing Partner of Catalio Capital Management, L.P. He is primarily responsible for managing the firm and for making investments in private breakthrough biomedical technology companies. He serves on the Investment Committee of Catalio’s flagship Nexus strategy and on the firmwide Management Committee.
George has served on several Boards of private healthcare companies, including Haystack Oncology (acquired by Quest Diagnostics), Octant Bio, DNA Script, Clasp Therapeutics and Odyssey Therapeutics. He also served as President of the HealthCor Catalio Special Purpose Acquisition Corp. (NASDAQ: HCAQ).
Prior to founding Catalio, he was a General Partner at Camden Partners Holdings, LLC, a private equity firm that spun-out of T. Rowe Price, where he focused on making healthcare investments.
On the non-profit side, George serves on the Board of Trustees of MoMA PS1, the Baltimore Museum of Art and the Chairman’s Council at the Whitney Museum of American Art, as well as the Advisory Board for the Johns Hopkins Center for Financial Economics.
George earned his B.A. degree in Financial Economics from the Johns Hopkins University.
